SecBot SecBot

EPIC Act of 2025

S. 832 Sen. Thomas Tillis (R-NC) In committee
Bill text PDF
  1. Introduced Mar 4
  2. Committee Mar 4
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 4, 2025Next: Senate vote
602d ago Mar 4, 2025: Read twice and referred to the Committee on Finance.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
9companies, 64 filings
Subscribe to see spend
Member trades
15trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

9 companies
Companies by sector
Biotech & Pharma 9
Search all 9 companies, their asks and price moves Subscribe

Summary

Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025

Full summary3 paragraphs

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.

Library of Congress summary, Mar 4, 2025

Summary versions
  • Introduced in SenateMar 4, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.